Biotech Rally Pauses But Clinical News and M&A Underpinnings Create Surge in ARRY and GWPH Stocks were weak across the screen today withe the NASDAQ down 0.91% as investors may be distracted by the upcoming Presidential debates and the plethora of opinions on election politics affecting the market. The XBI is just a tad off […]
Biotech ETFs Are Having A Strong Quarter and Offer Good Investment Options On July 20 we did a review of active funds vs biotech ETFs in the biotechnology/life science sector just after the BREXIT lows. At that time biotech ETFs and broadly diversified funds beat the “pure play” biotechnology funds such as Fidelity Select Biotechnology Portfolio […]
Update-1…FED Goes on Hold with Rate Increase Likely by Year End Three on FOMC dissented wanting a rate hike this round. Market immediately rallied with NASDAQ up 1.03% at close; S&P and Dow also rally. Biotechs like low i rates:IBB up 0.62% to $297, XBI up 1.14% to $68.28 highest level since January but still […]
Biopharma Stocks Breeze through ‘Quadruple Witching Day”…9/16 Healthcare stocks (XLV) were one of the leading sectors on a down day up a tiny bit to $72. The IBB held, up 0.57% to the $291 mark and up 4.75% for the week. The more volatile XBI was a tad weaker down 0.3% on the day. Large […]
Update-1… 9/13… Hard to Call Next Move: Macro and i Rates Rule The market was rattled at the opening with the IEA news on cuts in the demand forecast for crude which dropped 2.33%. Subsequently FED hike fears returned causing more volatility with stocks and significantly a major move up in the Ten Year Treasury Yield […]
Update-2…Market rallies Monday after 2% sell-off on Friday IBB held support at $280, up 1.9% today to 284 as of mid-morning . Mid-caps and large caps strong. —— Update-1… FED Rate Increase Fear Sparks Sell-Off NASDAQ down 1.14%, 10 Year Bond 1.67%, IBB down 1.4%, XBI down 1.64%… 11:30 am EDT. European bonds are also in a […]
M&A Deal of the Day: Cepheid (CPHD) up 50% Over Friday Close on Cash Buyout We have been spending too much time on biopharma. It is time to dust off our Dx and Tools portfolio, which is on hold, and find some value stocks for Q4 moves. We did an update in Q4 of 2015 […]
Update-2… 945 am EDT…Biotechs Hold Support IBB up 1.55% to $285 holding support at $280; XBI up 2.99% to $61.95 holding support at $60. Update-1…More Fallout from Mylan (MYL) EpiPen Drug Pricing MYL stock was down over 4% today on news that the EpiPen was mis-classified as a generic drug and that Medicaid was overcharged. […]
Update-1… IBB Trying to hold the $280 line after media bashing of EpiPen Pricing- now they have a generic EpiPen for half the price! Biotech outflows are a concern (-$184M) Gilead Sciences (GILD) down 2.89% on new potential competition from GlaxoSmithK (GSK) HIV double therapy drug with cost savings. Choppy market in biotech with red screen […]
Update-1 After Close 8/24 IBB at 286.23 XBI down 4.34% XLV down 1.54%, NASDAQ down 0.81% Early Afternoon Reversal Kills Biotech Rally In Heavy Trading But Mylan is not a biotech Company?? The broad based rally in biotech stocks faded around 1P EDT Wednesday as investors were spooked by the recurring political theme of high […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.